Oral GnRH antagonists, which include elagolix, relugolix, and linzagolix, signify a substantial progression, providing rapid and reversible suppression of ovarian hormone synthesis with dose-dependent effects and enhanced convenience. Innovative treatment modalities that target nonhormonal mechanisms, such as extracellular matrix remodeling, angiogenesis, and gene modulation, provide promising prospects for future uterus-sparing interventions. This narrative review evaluates the current and advancing landscape of medical therapies for uterine fibroids, presenting evidence-based perspectives to inform clinical decision-making within an increasingly personalized therapeutic context.

P2, N=40, Not yet recruiting, Antev Ltd.

In this first stage of a pilot study that awaits confirmation with larger numbers of patients, our results suggest that vaccination targeting AR given prior to androgen deprivation therapy might improve outcome for patients with high-risk prostate cancer. Contrary to our initial hypothesis, this was not improved with the addition of PD-1 blockade, possibly due to the activation of regulatory CD4+T cells.

P3, N=333, Recruiting, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Not yet recruiting --> Recruiting

P1/2, N=6, Active, not recruiting, M.D. Anderson Cancer Center | N=36 --> 6 | Recruiting --> Active, not recruiting

P1/2, N=50, Recruiting, IRCCS Istituto Nazionale Tumori Fondazione Pascale | Not yet recruiting --> Recruiting

P3, N=288, Active, not recruiting, Kissei Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting

P=N/A, N=33, Not yet recruiting, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

P2, N=94, Active, not recruiting, Emory University | Trial completion date: Dec 2025 --> Oct 2026

P3, N=254, Recruiting, JW Pharmaceutical

P3, N=333, Not yet recruiting, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

P2, N=30, Recruiting, Memorial Sloan Kettering Cancer Center